BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18772629)

  • 1. Usefulness of serial assessment of natriuretic peptides in the emergency department for patients with acute decompensated heart failure.
    Disomma S; Magrini L; Pittoni V; Marino R; Peacock WF; Maisel A
    Congest Heart Fail; 2008; 14(4 Suppl 1):21-4. PubMed ID: 18772629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure.
    Wong DT; George K; Wilson J; Manlhiot C; McCrindle BW; Adeli K; Kantor PF
    Am J Cardiol; 2011 Feb; 107(4):573-8. PubMed ID: 21295174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
    Maisel AS; Peacock WF; McMullin N; Jessie R; Fonarow GC; Wynne J; Mills RM
    J Am Coll Cardiol; 2008 Aug; 52(7):534-40. PubMed ID: 18687247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure.
    Di Somma S; Magrini L; Mazzone M; De Leva R; Tabacco F; Marino R; Talucci V; Ferri E; Forte P; Cardelli P; Gentiloni N; Pittoni V
    Am J Emerg Med; 2007 Mar; 25(3):335-9. PubMed ID: 17349910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure.
    Goonewardena SN; Gemignani A; Ronan A; Vasaiwala S; Blair J; Brennan JM; Shah DP; Spencer KT
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):595-601. PubMed ID: 19356487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inpatient monitoring and prognostic importance of B-type natriuretic peptide.
    Aspromonte N; Valle R; Peacock WF; Vanderheyden M; Maisel A
    Congest Heart Fail; 2008; 14(4 Suppl 1):30-4. PubMed ID: 18833664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure.
    Takahama H; Takashio S; Nishikimi T; Hayashi T; Nagai-Okatani C; Nakagawa Y; Amaki M; Ohara T; Hasegawa T; Sugano Y; Kanzaki H; Yasuda S; Kangawa K; Minamino N; Anzai T
    Int J Cardiol; 2018 May; 258():165-171. PubMed ID: 29544926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels.
    Valle R; Aspromonte N; Milani L; Peacock FW; Maisel AS; Santini M; Ronco C
    Heart Fail Rev; 2011 Nov; 16(6):519-29. PubMed ID: 21604179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure.
    Parrinello G; Paterna S; Di Pasquale P; Torres D; Fatta A; Mezzero M; Scaglione R; Licata G
    J Card Fail; 2008 Oct; 14(8):676-86. PubMed ID: 18926440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.
    Maisel A; Hollander JE; Guss D; McCullough P; Nowak R; Green G; Saltzberg M; Ellison SR; Bhalla MA; Bhalla V; Clopton P; Jesse R;
    J Am Coll Cardiol; 2004 Sep; 44(6):1328-33. PubMed ID: 15364340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure.
    De Berardinis B; Gaggin HK; Magrini L; Belcher A; Zancla B; Femia A; Simon M; Motiwala S; Bhardwaj A; Parry BA; Nagurney JT; Coudriou C; Legrand M; Sadoune M; Di Somma S; Januzzi JL;
    Clin Chem Lab Med; 2015 Mar; 53(4):613-21. PubMed ID: 25473804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utilization and prognostic impact of B-type Natriuretic Peptide in hospitalized acute decompensated heart failure in an Asian population.
    Chen LJ; Hung CL; Yeh HI; Jeng MJ; Su CH; Wu TY; Shih SC; Tsai CH
    BMC Cardiovasc Disord; 2016 Sep; 16(1):178. PubMed ID: 27613439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of BNP Variations in Patients Admitted for Acute Decompensated Heart Failure with In-Hospital Worsening Renal Function.
    Stolfo D; Stenner E; Merlo M; Porto AG; Moras C; Barbati G; Aleksova A; Buiatti A; Sinagra G
    Heart Lung Circ; 2017 Mar; 26(3):226-234. PubMed ID: 27523462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure.
    Potocki M; Breidthardt T; Reichlin T; Hartwiger S; Morgenthaler NG; Bergmann A; Noveanu M; Freidank H; Taegtmeyer AB; Wetzel K; Boldanova T; Stelzig C; Bingisser R; Christ M; Mueller C
    J Intern Med; 2010 Jan; 267(1):119-29. PubMed ID: 19570053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic Peptide and the diagnosis of acute heart failure.
    Berkowitz R
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S3-16. PubMed ID: 15627917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-B-type natriuretic peptide levels in acute decompensated heart failure.
    Waldo SW; Beede J; Isakson S; Villard-Saussine S; Fareh J; Clopton P; Fitzgerald RL; Maisel AS
    J Am Coll Cardiol; 2008 May; 51(19):1874-82. PubMed ID: 18466803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide show a different profile in response to acute decompensated heart failure treatment.
    Di Somma S; Magrini L; Tabacco F; Marino R; Talucci V; Marrocco F; Cardelli P; Ferri E; Pittoni V
    Congest Heart Fail; 2008; 14(5):245-50. PubMed ID: 18983287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.
    Chiong JR; Jao GT; Adams KF
    Heart Fail Rev; 2010 Jul; 15(4):275-91. PubMed ID: 19360469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment.
    Stienen S; Salah K; Dickhoff C; Carubelli V; Metra M; Magrini L; Di Somma S; Tijssen JP; Pinto YM; Kok WE
    J Card Fail; 2015 Nov; 21(11):930-4. PubMed ID: 26216495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study.
    Di Somma S; Magrini L; Pittoni V; Marino R; Mastrantuono A; Ferri E; Ballarino P; Semplicini A; Bertazzoni G; Carpinteri G; Mulè P; Pazzaglia M; Shah K; Maisel A; Clopton P
    Crit Care; 2010; 14(3):R116. PubMed ID: 20550660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.